Proteomic biomarkers in lung cancer

Clinical and Translational Oncology

Volumn 15, Issue 9, 2013, Pages 671-682

  Pastor, M D ^a   Nogal, A ^a,b   Molina Pinelo, S ^a   Carnero, A ^a   Paz Ares, L ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Diagnostic biomarkers; Lung cancer; Predictive biomarkers; Prognostic biomarkers; Proteomics

Indexed keywords

TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; HUMAN; ISOTOPE LABELING; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MASS SPECTROMETRY; PREDICTIVE VALUE; PROTEIN ANALYSIS; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOTOPE LABELING; LUNG NEOPLASMS; MASS SPECTROMETRY; PROTEOME; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84883298050     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-013-1034-0     Document Type: Article

References (82)

1. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2012. Ann Oncol. 2012;23(4):1044-52.
2. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest. 2003;123(1 Suppl):21S-49S.
3. Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edn). Chest. 2007;132(3 Suppl):29S-55S.
4. Agullo-Ortuno MT, Lopez-Rios F, Paz-Ares L. Lung cancer genomic signatures. J Thorac Oncol. 2010;5(10):1673-91.
5. Meyerson M, Franklin WA, Kelley MJ. Molecular classification and molecular genetics of human lung cancers. Semin Oncol. 2004;1(Suppl 1):4-19.
6. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367-80.
7. Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. 2012;150(6):1121-34.
8. Ocak S, Chaurand P, Massion PP. Mass spectrometry-based proteomic profiling of lung cancer. Proc Am Thorac Soc. 2009;6(2):159-70.
9. Hirsch J, Hansen KC, Burlingame AL, Matthay MA. Proteomics: current techniques and potential applications to lung disease. Am J Physiol Lung Cell Mol Physiol. 2004;287(1):L1-23.
10. Conrad DH, Goyette J, Thomas PS. Proteomics as a method for early detection of cancer: a review of proteomics, exhaled breath condensate, and lung cancer screening. J Gen Intern Med. 2008;23(Suppl 1):78-84.
11. Massion PP, Caprioli RM. Proteomic strategies for the characterization and the early detection of lung cancer. J Thorac Oncol. 2006;1(9):1027-39.
12. Guerrera IC, Keep NH, Godovac-Zimmermann J. Proteomics study reveals cross-talk between Rho guanidine nucleotide dissociation inhibitor 1 post-translational modifications in epidermal growth factor stimulated fibroblasts. J Proteome Res. 2007;6(7):2623-30.
13. Mann M. Functional and quantitative proteomics using SILAC. Nat Rev Mol Cell Biol. 2006;7(12):952-8.
14. Graves PR, Haystead TA. Molecular biologist's guide to proteomics. Microbiol Mol Biol Rev. 2002;66(1):39-63; table of contents.
15. DeSouza L, Diehl G, Rodrigues MJ, Guo J, Romaschin AD, Colgan TJ, et al. Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry. J Proteome Res. 2005;4(2):377-86.
16. Bowler RP, Ellison MC, Reisdorph N. Proteomics in pulmonary medicine. Chest. 2006 Aug;130(2):567-74.
17. De Petris L, Pernemalm M, Elmberger G, Bergman P, Orre L, Lewensohn R, et al. A novel method for sample preparation of fresh lung cancer tissue for proteomics analysis by tumor cell enrichment and removal of blood contaminants. Proteome Science. 2010;8:9.
18. Magi B, Bargagli E, Bini L, Rottoli P. Proteome analysis of bronchoalveolar lavage in lung diseases. Proteomics. 2006;6(23):6354-69.
19. Gray RD, MacGregor G, Noble D, Imrie M, Dewar M, Boyd AC, et al. Sputum proteomics in inflammatory and suppurative respiratory diseases. Am J Respir Crit Care Med. 2008;178(5):444-52.
20. Zhang Y, Li Y, Qiu F, Qiu Z. Comparative analysis of the human urinary proteome by 1D SDS-PAGE and chip-HPLC-MS/MS identification of the AACT putative urinary biomarker. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878(32):3395-401.
21. Xiao H, Zhang L, Zhou H, Lee JM, Garon EB, Wong DT. Proteomic analysis of human saliva from lung cancer patients using two-dimensional difference gel electrophoresis and mass spectrometry. Mol Cell Proteomics. 2012;11(2):M111 012112.
22. Campa MJ, Wang MZ, Howard B, Fitzgerald MC, Patz EF, Jr. Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer. Cancer Res. 2003;63(7):1652-6.
23. Xiao T, Ying W, Li L, Hu Z, Ma Y, Jiao L, et al. An approach to studying lung cancer-related proteins in human blood. Mol Cell Proteomics. 2005;4(10):1480-6.
24. Rahman SM, Gonzalez AL, Li M, Seeley EH, Zimmerman LJ, Zhang XJ, et al. Lung cancer diagnosis from proteomic analysis of preinvasive lesions. Cancer Res. 2011;71(8):3009-17.
25. White ES, Flaherty KR, Carskadon S, Brant A, Iannettoni MD, Yee J, et al. Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin Cancer Res. 2003;9(2):853-60.
26. Brichory F, Beer D, Le Naour F, Giordano T, Hanash S. Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res. 2001;61(21):7908-12.
27. Okano T, Kondo T, Kakisaka T, Fujii K, Yamada M, Kato H, et al. Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis. Proteomics. 2006;6(13):3938-48.
28. Kang SM, Sung HJ, Ahn JM, Park JY, Lee SY, Park CS, et al. The Haptoglobin beta chain as a supportive biomarker for human lung cancers. Mol Biosyst. 2011;7(4):1167-75.
29. Patz EF, Jr, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR, Herndon JE, 2nd. Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol. 2007;25(35):5578-83.
30. Song QB, Hu WG, Wang P, Yao Y, Zeng HZ. Identification of serum biomarkers for lung cancer using magnetic bead-based SELDI-TOF-MS. Acta Pharmacol Sin. 2011;32(12):1537-42.
31. Sung HJ, Ahn JM, Yoon YH, Rhim TY, Park CS, Park JY, et al. Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer. J Proteome Res. 2011;10(3):1383-95.
32. Yildiz PB, Shyr Y, Rahman JS, Wardwell NR, Zimmerman LJ, Shakhtour B, et al. Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. J Thorac Oncol. 2007;2(10):893-901.
33. Liu L, Liu J, Dai S, Wang X, Wu S, Wang J, et al. Reduced transthyretin expression in sera of lung cancer. Cancer Sci. 2007;98(10):1617-24.
34. Yu CJ, Wang CL, Wang CI, Chen CD, Dan YM, Wu CC, et al. Comprehensive proteome analysis of malignant pleural effusion for lung cancer biomarker discovery by using multidimensional protein identification technology. J Proteome Res. 2011;10(10):4671-82.
35. Okuzawa K, Franzen B, Lindholm J, Linder S, Hirano T, Bergman T, et al. Characterization of gene expression in clinical lung cancer materials by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis. 1994;15(3-4):382-90.
36. Jeong HC, Kim GI, Cho SH, Lee KH, Ko JJ, Yang JH, et al. Proteomic analysis of human small cell lung cancer tissues: up-regulation of coactosin-like protein-1. J Proteome Res. 2011;10(1):269-76.
37. Tanca A, Addis MF, Pagnozzi D, Cossu-Rocca P, Tonelli R, Falchi G, et al. Proteomic analysis of formalin-fixed, paraffin-embedded lung neuroendocrine tumor samples from hospital archives. J Proteomics. 2011;74(3):359-70.
38. Lee HS, Park JW, Chertov O, Colantonio S, Simpson JT, Fivash MJ, et al. Matrix-assisted laser desorption/ionization mass spectrometry reveals decreased calcylcin expression in small cell lung cancer. Pathol Int. 2012;62(1):28-35.
39. Bharti A, Ma PC, Maulik G, Singh R, Khan E, Skarin AT, et al. Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer. Anticancer Res. 2004;24(2C):1031-8.
40. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 2010;10(8):537-49.
41. Pastorekova S, Parkkila S, Pastorek J, Supuran CT. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem. 2004;19(3):199-229.
42. Li LS, Kim H, Rhee H, Kim SH, Shin DH, Chung KY, et al. Proteomic analysis distinguishes basaloid carcinoma as a distinct subtype of nonsmall cell lung carcinoma. Proteomics. 2004;4(11):3394-400.
43. Park JH, Kim YS, Lee HL, Shim JY, Lee KS, Oh YJ, et al. Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung. Respirology. 2006;11(3):269-75.
44. Park HJ, Kim BG, Lee SJ, Heo SH, Kim JY, Kwon TH, et al. Proteomic profiling of endothelial cells in human lung cancer. J Proteome Res. 2008;7(3):1138-50.
45. Gamez-Pozo A, Sanchez-Navarro I, Calvo E, Agullo-Ortuno MT, Lopez-Vacas R, Diaz E, et al. PTRF/cavin-1 and MIF proteins are identified as non-small cell lung cancer biomarkers by label-free proteomics. PLoS One. 2012;7(3):e33752.
46. Yanagisawa K, Tomida S, Shimada Y, Yatabe Y, Mitsudomi T, Takahashi T. A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer. J Natl Cancer Inst. 2007;99(11):858-67.
47. Hoagland LFt, Campa MJ, Gottlin EB, Herndon JE, 2nd, Patz EF, Jr. Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer. Cancer. 2007;110(10):2260-8.
48. Howard BA, Wang MZ, Campa MJ, Corro C, Fitzgerald MC, Patz EF, Jr. Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ionization-time of flight spectra analysis. Proteomics. 2003;3(9):1720-4.
49. Rodriguez-Pineiro AM, Blanco-Prieto S, Sanchez-Otero N, Rodriguez-Berrocal FJ, de la Cadena MP. On the identification of biomarkers for non-small cell lung cancer in serum and pleural effusion. J Proteomics. 2010;73(8):1511-22.
50. Li Y, Zhang Y, Qiu F, Qiu Z. Proteomic identification of exosomal LRG1: a potential urinary biomarker for detecting NSCLC. Electrophoresis. 2011;32(15):1976-83.
51. Chen G, Gharib TG, Huang CC, Thomas DG, Shedden KA, Taylor JM, et al. Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res. 2002;8(7):2298-305.
52. Rho JH, Roehrl MH, Wang JY. Tissue proteomics reveals differential and compartment-specific expression of the homologs transgelin and transgelin-2 in lung adenocarcinoma and its stroma. J Proteome Res. 2009;8(12):5610-8.
53. Xiao G, Lu Q, Li C, Wang W, Chen Y, Xiao Z. Comparative proteome analysis of human adenocarcinoma. Med Oncol. 2010;27(2):346-56.
54. Peng XC, Gong FM, Zhao YW, Zhou LX, Xie YW, Liao HL, et al. Comparative proteomic approach identifies PKM2 and cofilin-1 as potential diagnostic, prognostic and therapeutic targets for pulmonary adenocarcinoma. PLoS One. 2011;6(11):e27309.
55. Maciel CM, Junqueira M, Paschoal ME, Kawamura MT, Duarte RL, Carvalho Mda G, et al. Differential proteomic serum pattern of low molecular weight proteins expressed by adenocarcinoma lung cancer patients. J Exp Ther Oncol. 2005;5(1):31-8.
56. Pernemalm M, De Petris L, Eriksson H, Branden E, Koyi H, Kanter L, et al. Use of narrow-range peptide IEF to improve detection of lung adenocarcinoma markers in plasma and pleural effusion. Proteomics. 2009;9(13):3414-24.
57. Li C, Xiao Z, Chen Z, Zhang X, Li J, Wu X, et al. Proteome analysis of human lung squamous carcinoma. Proteomics. 2006;6(2):547-58.
58. Xu Y, Cao LQ, Jin LY, Chen ZC, Zeng GQ, Tang CE, et al. Quantitative proteomic study of human lung squamous carcinoma and normal bronchial epithelial acquired by laser capture microdissection. J Biomed Biotechnol. 2012;2012:510418.
59. Li B, Chang J, Chu Y, Kang H, Yang J, Jiang J, et al. Membrane proteomic analysis comparing squamous cell lung cancer tissue and tumour-adjacent normal tissue. Cancer Lett. 2012;319(1):118-24.
60. Tan F, Jiang Y, Sun N, Chen Z, Lv Y, Shao K, et al. Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis. Mol Cell Proteomics. 2012;11(2):M111 008821.
61. Yang F, Xiao ZQ, Zhang XZ, Li C, Zhang PF, Li MY, et al. Identification of tumor antigens in human lung squamous carcinoma by serological proteome analysis. J Proteome Res. 2007;6(2):751-8.
62. Dowling P, O'Driscoll L, Meleady P, Henry M, Roy S, Ballot J, et al. 2-D difference gel electrophoresis of the lung squamous cell carcinoma versus normal sera demonstrates consistent alterations in the levels of ten specific proteins. Electrophoresis. 2007;28(23):4302-10.
63. Yanagisawa K, Shyr Y, Xu BJ, Massion PP, Larsen PH, White BC, et al. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet. 2003;362(9382):433-9.
64. Xu BJ, Gonzalez AL, Kikuchi T, Yanagisawa K, Massion PP, Wu H, et al. MALDI-MS derived prognostic protein markers for resected non-small cell lung cancer. Proteomics Clin Appl. 2008;2(10-11):1508-17.
65. De Petris L, Orre LM, Kanter L, Pernemalm M, Koyi H, Lewensohn R, et al. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer. Lung Cancer. 2009;63(3):410-7.
66. Gharib TG, Chen G, Wang H, Huang CC, Prescott MS, Shedden K, et al. Proteomic analysis of cytokeratin isoforms uncovers association with survival in lung adenocarcinoma. Neoplasia. 2002;4(5):440-8.
67. Chen G, Gharib TG, Wang H, Huang CC, Kuick R, Thomas DG, et al. Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci U S A. 2003;100(23):13537-42.
68. Liu YF, Xiao ZQ, Li MX, Li MY, Zhang PF, Li C, et al. Quantitative proteome analysis reveals annexin A3 as a novel biomarker in lung adenocarcinoma. J Pathol. 2009;217(1):54-64.
69. Liu YF, Chen YH, Li MY, Zhang PF, Peng F, Li GQ, et al. Quantitative proteomic analysis identifying three annexins as lymph node metastasis-related proteins in lung adenocarcinoma. Med Oncol. 2012;29(1):174-84.
70. Maeda J, Hirano T, Ogiwara A, Akimoto S, Kawakami T, Fukui Y, et al. Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy. Br J Cancer. 2008;98(3):596-603.
71. Li DJ, Deng G, Xiao ZQ, Yao HX, Li C, Peng F, et al. Identificating 14-3-3 sigma as a lymph node metastasis-related protein in human lung squamous carcinoma. Cancer Lett. 2009;279(1):65-73.
72. Yao H, Zhang Z, Xiao Z, Chen Y, Li C, Zhang P, et al. Identification of metastasis associated proteins in human lung squamous carcinoma using two-dimensional difference gel electrophoresis and laser capture microdissection. Lung Cancer. 2009;65(1):41-8.
73. Okano T, Kondo T, Fujii K, Nishimura T, Takano T, Ohe Y, et al. Proteomic signature corresponding to the response to gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma. Clin Cancer Res. 2007;13(3):799-805.
74. Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K, et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst. 2007;99(11):838-46.
75. Amann JM, Lee JW, Roder H, Brahmer J, Gonzalez A, Schiller JH, et al. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. J Thorac Oncol. 2010;5(2):169-78.
76. Carbone DP, Ding K, Roder H, Grigorieva J, Roder J, Tsao MS, et al. Prognostic and predictive role of the veristrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 Trial. J Thorac Oncol. 2012;7(11):1653-60.
77. Carbone DP, Salmon JS, Billheimer D, Chen H, Sandler A, Roder H, et al. VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer. 2010;69(3):337-40.
78. Chung CH, Seeley EH, Roder H, Grigorieva J, Tsypin M, Roder J, et al. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol Biomarkers Prev. 2010;19(2):358-65.
79. Gautschi O, Dingemans AM, Crowe S, Peters S, Roder H, Grigorieva J, et al. VeriStrat((R)) has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528. Lung Cancer. 2013;79(1):59-64.
80. Kuiper JL, Lind JS, Groen HJ, Roder J, Grigorieva J, Roder H, et al. VeriStrat((R)) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib. Br J Cancer. 2012;107(11):1820-5.
81. Lazzari C, Spreafico A, Bachi A, Roder H, Floriani I, Garavaglia D, et al. Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors. J Thorac Oncol. 2012;7(1):40-8.
82. Milan E, Lazzari C, Anand S, Floriani I, Torri V, Sorlini C, et al. SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors. J Proteomics. 2012.